Lannett Co Inc (LCI)
(Delayed Data from NYSE)
$8.54 USD
+0.70 (8.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.54 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.54 USD
+0.70 (8.93%)
Updated May 3, 2019 04:00 PM ET
After-Market: $8.54 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Bausch (BHC) Beats on Q3 Earnings & Sales, Raises Guidance
by Zacks Equity Research
Bausch (BHC) beats on sales and earnings in the third quarter and raises annual guidance.
Endo (ENDP) Q3 Earnings & Revenues Beat Estimates, Down Y/Y
by Zacks Equity Research
Endo (ENDP) reports better-than-expected results for the third quarter as Xiaflex delivers a strong performance.
Lannett (LCI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Lannett (LCI) closed at $11.88, marking a -1% move from the previous day.
Analysts Estimate Lannett (LCI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Lannett (LCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lannett (LCI) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Lannet's (LCI) fiscal first-quarter 2020 results are likely to reflect strong performance of its anti-psychosis and cardiovascular drugs.
Lannett (LCI) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Lannett (LCI) closed the most recent trading day at $12.26, moving +1.16% from the previous trading session.
Is Lannett Co (LCI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (LCI) Outperforming Other Medical Stocks This Year?
Lannett (LCI) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Lannett (LCI) closed at $11.73 in the latest trading session, marking a -1.84% move from the prior day.
The Zacks Analyst Blog Highlights: NRG Energy, Lannett Company, Genesis Healthcare, US Foods and Grocery Outlet
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NRG Energy, Lannett Company, Genesis Healthcare, US Foods and Grocery Outlet
Buy These 5 Defensive Stocks to Counter Market Volatility
by Zacks Equity Research
Markets have turned volatile due to poor economic data and geopolitical tensions, here are five defensive stocks to boost your portfolio.
Lannett (LCI) Stock Moves -0.9%: What You Should Know
by Zacks Equity Research
Lannett (LCI) closed at $12.18 in the latest trading session, marking a -0.9% move from the prior day.
Is Lannett Co (LCI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (LCI) Outperforming Other Medical Stocks This Year?
Top Ranked Momentum Stocks to Buy for October 1st
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 1st
Will Lannett Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Lannett Company.
Lannett (LCI) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Lannett (LCI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Top Ranked Momentum Stocks to Buy for September 19th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 19th
Moving Average Crossover Alert: Lannett Company
by Zacks Equity Research
Lannett Company is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front
Ardelyx (ARDX) in Focus: Stock Moves 8.3% Higher
by Zacks Equity Research
Ardelyx (ARDX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Small Drug Stock Outlook: Innovation Holds the Key to Growth
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Lannett (LCI) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Lannett (LCI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is the Options Market Predicting a Spike in Lannett (LCI) Stock?
by Zacks Equity Research
Investors need to pay close attention to Lannett (LCI) stock based on the movements in the options market lately.
Ensign Group to Spin Off Home Health & Hospice Business
by Zacks Equity Research
Ensign Group (ENSG) to separate its home health and hospice business from the parent company.
Catalyst Pharmaceuticals (CPRX) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Lannett (LCI) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Lannett (LCI) delivered earnings and revenue surprises of 76.19% and 9.68%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Lannett (LCI) Q4 Earnings Expected to Decline
by Zacks Equity Research
Lannett (LCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.